Advertisement

36-Year-Old Female with Bright Red Plaques on the Labia Majora

  • Kevin K. Wu
  • Michael P. Lee
  • Jashin J. Wu
Chapter
Part of the Clinical Cases in Dermatology book series (CLIDADE)

Abstract

Genital psoriasis presents with thin, erythematous, well-defined plaques with minimal scaling. Patients affected by genital psoriasis may feel embarrassment and avoid discussing their concerns with their clinician, leading to delayed care. First-line therapies include low potency topical corticosteroids, topical vitamin D analogs, topical calcineurin inhibitors, and crisaborole.

Keywords

Genital psoriasis Sexual dysfunction Vitamin D analog Calcineurin inhibitor Crisaborole Topical corticosteroid Ixekizumab 

References

  1. 1.
    Meeuwis KA, de Hullu JA, de Jager ME, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands. J Eur Acad Dermatol Venereol. 2010;24(12):1425–30.  https://doi.org/10.1111/j.1468-3083.2010.03663.x.CrossRefPubMedGoogle Scholar
  2. 2.
    Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW, Massuger LF, van de Kerkhof PC, van Rossum MM. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011b;164(6):1247–55.  https://doi.org/10.1111/j.1365-2133.2011.10249.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Ryan C, Sadlier M, De Vol E, Patel M, Lloyd AA, Day A, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978–83.  https://doi.org/10.1016/j.jaad.2015.02.1127.CrossRefPubMedGoogle Scholar
  4. 4.
    Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol. 2011a;91(1):5–11.  https://doi.org/10.2340/00015555-0988.CrossRefPubMedGoogle Scholar
  5. 5.
    Zamirska A, Reich A, Berny-Moreno J, Salomon J, Szepietowski JC. Vulvar pruritus and burning sensation in women with psoriasis. Acta Derm Venereol. 2008;88(2):132–5.  https://doi.org/10.2340/00015555-0372.CrossRefPubMedGoogle Scholar
  6. 6.
    Buechner SA. Common skin disorders of the penis. BJU Int. 2002;90(5):498–506.CrossRefGoogle Scholar
  7. 7.
    Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, et al. Treatment of intertriginous psoriasis: from the medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(1):120–4.  https://doi.org/10.1016/j.jaad.2008.06.041.CrossRefPubMedGoogle Scholar
  8. 8.
    Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg. 2008;12(5):230–4.  https://doi.org/10.2310/7750.2008.07055.CrossRefPubMedGoogle Scholar
  9. 9.
    Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki-Schulze A, Koumantaki E, Karpouzis A, Arvanitis A. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res. 2005;31(4):141–5.PubMedGoogle Scholar
  10. 10.
    Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(−1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol. 2007;157(5):1005–12.  https://doi.org/10.1111/j.1365-2133.2007.08201.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Lee EB, Lebwohl MG, Wu JJ. Treatment of psoriasis with crisaborole. J Dermatolog Treat. 2018;30:1–2.  https://doi.org/10.1080/09546634.2018.1480747.CrossRefGoogle Scholar
  12. 12.
    Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503 e496.  https://doi.org/10.1016/j.jaad.2016.05.046.CrossRefPubMedGoogle Scholar
  13. 13.
    Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179:844–52.  https://doi.org/10.1111/bjd.16736.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kevin K. Wu
    • 1
  • Michael P. Lee
    • 2
  • Jashin J. Wu
    • 3
  1. 1.Frank H. Netter MD School of Medicine at Quinnipiac UniversityNorth HavenUSA
  2. 2.Eastern Virginia Medical SchoolNorfolkUSA
  3. 3.Founder and CEODermatology Research and Education FoundationIrvineUSA

Personalised recommendations